AMCS
14.8.2024 12:56:29 CEST | Business Wire | Press release
AMCS, a global leader of sustainability software for foundational industries, and EQT Private Equity are pleased to announce that EQT X and EQT Future (jointly "EQT Private Equity") will acquire a majority stake in the Company. The co-founder, management, and other existing investors, including existing majority investor Insight Partners, as well as Clearlake Capital, Highland Europe and the Ireland Strategic Investment Fund, are expected to retain minority stakes.
Founded in 2003, and headquartered in Ireland, AMCS serves resource-intensive industries, including waste management, recycling, transportation, manufacturing, and utilities. With its industry leading SaaS platform, which includes Enterprise Resource Planning, recycling, transport, and EHSQ & ESG software, AMCS is strongly positioned to support its customers’ needs and shift towards a more circular economy. AMCS’ market is growing quickly thanks to secular tailwinds including the growth in complexity associated with shifting to greater circularity in supply chains, as well as cloud software adoption trends, and increasing regulatory and sustainability reporting.
AMCS' solutions help to deliver increased performance and efficiency in its customers’ operations, while also supporting them to deliver on their sustainability goals and meet regulatory requirements. AMCS’ customers include some of the largest waste management and recycling companies globally, as well as blue-chip manufacturing customers. With over 1,300 employees across Europe, North America and Australasia, AMCS serves over 3800 customers, across 80 countries, and helps manage more than 700,000 vehicles globally.
The partnership with AMCS represents a highly thematic investment for both EQT X and EQT Future. EQT Private Equity will contribute its extensive experience in software value creation and impact acceleration to support the Company’s growth and sustainability ambitions. More than two billion tons of waste is generated annually, resulting in one billion tons of CO2 and 3.2 percent of global emissions1, hence the clear need for solutions that can eventually support the transition to a circular economy. AMCS’ solutions sit at the heart of its customers’ operations and, given its leadership position, have tremendous potential to improve resource efficiency for the industry as a whole.
Performance Sustainability: Sustainability That Means Business
AMCS’ Performance Sustainability Suite is the operating system for foundational industries that makes sustainability and profitability possible. The suite manages the running of day-to-day operations such as contracts and pricing, logistics and transportation, materials and resources, health and safety, and sustainability intelligence. The AMCS Performance Sustainability Suite drives growth and profitability, optimizes efficiency and safety, powers corporate sustainability initiatives, and prepares businesses for the circular economy and the future. With AMCS, businesses can improve performance and scale more easily, enabling foundational industry professionals to leave the planet in a better way than they found it.
Jimmy Martin, co-founder and CEO, AMCS, said: “On behalf of AMCS, I'd like to express our deepest gratitude to EQT, for aligning with our vision of empowering sustainability for organizations globally and championing the circular economy. Their backing is instrumental in supporting the transformative work we do. I’d like to also thank our dedicated, long-standing investors Insight Partners, Clearlake Capital, Highland Europe, and the Ireland Strategic Investment Fund. These pillars of our capital structure have shown once again their unwavering faith in AMCS through their renewed support. Our shared commitment with our investors is the fuel that drives AMCS to solidify our pivotal role as a leader in Performance Sustainability.”
Robert Maclean, Partner in the EQT Private Equity advisory team, said: “We have followed the progress of AMCS closely for many years and have been hugely impressed by what it has achieved, establishing itself as a clear market leader and delivering continuous innovation on behalf of its customers. We strongly believe that AMCS has a fantastic opportunity to further support the circular economy and drive a greater share of recycling within the waste industry. We are very pleased to be partnering with AMCS’ co-founder and CEO Jimmy Martin as well as his entire team, to deliver on an exciting, shared vision for growth.”
Simon Griffiths, Head of the EQT Future advisory team, said: “Our investment in AMCS is strongly aligned with EQT Future’s focus on leading businesses, where the market opportunity and the very strong decarbonisation impact angle support a long-term investment horizon. We believe that AMCS is clearly positioned to be a long-term winner as the world shifts to a circular economy, and we look forward to supporting AMCS to help drive this trend and deliver on its growth ambitions."
Richard Wells, Managing Director at Insight Partners, said: “Since our initial investment in 2015, Insight has had the privilege of supporting AMCS as it scaled into a global market leader driving positive change towards a more circular economy. We look forward to deepening our support of AMCS, led by co-founder and CEO Jimmy Martin, in partnership with EQT as the business continues to innovate and grow."
The transaction is subject to customary conditions and approvals. It is expected to close before Q1 2025.
William Blair & Company served as exclusive financial advisor to AMCS. Willkie Farr & Gallagher served as legal counsel to Insight Partners. Arma Partners served as exclusive financial advisor and Clifford Chance as legal counsel to EQT.
About EQT
EQT is a purpose-driven global investment organization with EUR 246 billion in total assets under management (EUR 133 billion in fee-generating assets under management), within two business segments – Private Capital and Real Assets. EQT owns portfolio companies and assets in Europe, Asia-Pacific and the Americas and supports them in achieving sustainable growth, operational excellence and market leadership. Learn more at: www.eqtgroup.com. Follow EQT on LinkedIn, X, YouTube and Instagram.
About Insight Partners
Insight Partners is a global software investor partnering with high-growth technology, software, and Internet startup and ScaleUp companies that are driving transformative change in their industries. As of December 31, 2023, the firm has over $80B in regulatory assets under management. Insight Partners has invested in more than 800 companies worldwide and has seen over 55 portfolio companies achieve an IPO. Headquartered in New York City, Insight has offices in London, Tel Aviv, and the Bay Area. Insight’s mission is to find, fund, and work successfully with visionary executives, providing them with tailored, hands-on software expertise along their growth journey, from their first investment to IPO. For more information on Insight and all its investments, visit insightpartners.com or follow us on X @insightpartners.
About AMCS
At AMCS we are focused on Performance Sustainability – enabling resource-intensive industries to boost sustainability and profitability. Built on decades of experience, our purpose-built software solutions are designed by people who understand your business, providing practical solutions for the resources, waste, recycling, transportation, manufacturing, and utilities industries.
Headquartered in Ireland, and with offices in Europe, the USA, and Australia, AMCS is a global market leader with over 1,300 mission-driven team members. The combined expertise of our team allows AMCS to deliver innovative solutions and extensive insight, helping customers to drive growth and achieve lasting success. As a trusted global partner, we work with 3800 customers in more than 80 countries delivering digital solutions that create meaningful and measurable impact by increasing customer satisfaction, enhancing sustainability, and boosting margins.
At AMCS, we're ready to innovate with you - deploying our experts, processes, and technology to drive your business forward and prepare you for success in a more sustainable, net zero carbon future. Learn more at: www.amcsgroup.com
1 World Bank; Climate Watch; the World Resource Institute.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240813785675/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
